Background: In 1991, the first world survey of neuromuscular disorders (NMDs) was published in the peer reviewed literature. Since then, diagnostics have been greatly improved through genetic confirmation and consensus on criteria. This prompted us to search the scientific literature since 1990 for the epidemiology of NMDs. Objectives: To study occurrence rates, gender and age distribution. Methods: Pubmed was searched for 'epidemiology', 'incidence' and 'prevalence' regarding thirty NMDs for peer reviewed literature from 1990-2014. Results: We found incidence rates for ten disorders, ranging from 0.05 to 9 per 100,000/yr. Most NMDs showed prevalence rates between 1 and 10 per 100,000 population, except for multifocal motor neuropathy, Lambert-Eaton myasthenic syndrome, Emery-Dreifuss dystrophy, oculopharyngeal muscular dystrophy, and congenital muscular dystrophies, which were <1/100,000. Post-polio syndrome and Charcot-Marie-Tooth disease revealed prevalences >10/100,000. Information regarding incidence, prevalence, age distribution and gender was complete for eight disorders. No data were found for chronic inflammatory demyelinating polyneuropathy, neuralgic amyotrophy, progressive spinal muscular atrophy, McArdle's and Pompe's disease. For the 17 remaining disorders, information was partially available. Conclusions: Compared to 1991, prevalence rates of Becker muscular dystrophy, facioscapulohumeral dystrophy, myotonic dystrophy and Charcot-Marie-Tooth disease showed increase, yet with highly overlapping ranges with the exception of myotonic dystrophy. The sum of the available prevalence rates comprises only the tip of the iceberg, but is already in range with the prevalence of Parkinson's disease. Although individual NMDs are rare, as a group they are not.
INTRODUCTION
Knowledge on disease mechanisms of neuromuscular disorders is growing fast, facilitating identification of potential therapeutic targets [1, 2] . As clinical studies on interventions can be expected in the near future, reliable information regarding disease epidemiology is needed for trial readiness and will help to identify gaps 1 Authors contributed equally. * Correspondence to: Johanna C.W. Deenen in the knowledge on the epidemiology of neuromuscular disorders.
In 1991, the first world survey of mostly inheritable neuromuscular disorders was published in the peer reviewed literature [3, 4] . In addition, Great Britain's patient association Muscular Dystrophy Campaign presented a report in 2010 that included thirteen groups of neuromuscular diseases [5] . Three years later, Orphanet reported on the prevalence of rare diseases, including neuromuscular disorders as those are almost invariably rare [6] .
Since the 1991 survey, genetic confirmation of various neuromuscular disorders has become common practice. Also, consensus on diagnostic criteria was reached for a number of diseases [7] . Therefore, we expanded the scope of the first world survey by investigating the epidemiology of thirty disorders, that are either relatively frequent, or have a particular distinguishable phenotype. We searched published peer reviewed literature for available incidence and prevalence rates and for information regarding the distribution of age and gender within the diseases. With this overview, we aim to give useful estimates of prevalence, incidence and age and gender distribution based on the recent world literature.
MATERIALS AND METHODS

Search terms, period and inclusion criteria
We searched Pubmed for thirty neuromuscular disorders frequently seen or clearly distinguishable in the neuromuscular clinic, using the mentioned disease names as search term (Table 1) . Symptomatic disorders such as neuropathies secondary to HIV or diabetes mellitus were excluded. We additionally searched for articles using the terms neuromuscular disorder, neuromuscular disease, neurological disorder, or muscle disease in the title. We combined all search terms with the keywords epidemiology, incidence, and prevalence in the title and as MeSH term. We studied the peer reviewed literature published between January 1990 up until July 2014. Inclusion criteria were: published in English, research concerning humans, looking into one of the 30 scrutinised neuromuscular disorders, in case of multiple publications of the same or overlapping data: inclusion of the most recently reported data only, concerning the general population and not specific subgroup(s), findings for the overall disorder, no specific disease type(s), containing information regarding incidence or prevalence rates, original data therefore excluding reviews, and finally, methods of ascertainment and calculation of disease frequency needed to be mentioned in the article.
Frequency measures
Selected articles were scrutinised for incidence and prevalence rates. To facilitate comparison, estimates that used the number of live births as the denominator (birth prevalences) were excluded. In addition, all prevalence rates were standardised into units of 100,000 persons and all incidence rates into units of 100,000 persons per year. Next, the articles containing data regarding incidence or prevalence were searched for information about gender and age distribution. We classified the age at diagnosis of each disorder as early, uniform or late, depending on the highest frequency of the occurrence rates and their range. For gender, we reported the percentage of males within the total group of patients per disease.
Summarising the findings
We presented the range of the identified rates, the number of estimates and we calculated the mean and median of the findings. Means and medians were rounded to one significant digit, thus reporting on the general order of magnitude rather than seemingly exact numbers. We did not perform significance tests or determine confidence intervals for comparisons, as these would imply a level of precision that does not match the methods applied or our aim to present the general order of magnitude of the rates rather than exact numbers.
RESULTS
We identified 169 articles containing relevant information on one or more of the 30 specified disorders (Table 1) . Incidence and prevalence rates and data about gender and age were found for eight of the thirty neuromuscular disorders: amyotrophic lateral sclerosis, chronic inflammatory demyelinating polyneuropathy, Friedreich ataxia, myasthenia gravis, Lambert-Eaton myasthenic syndrome, polymyositis, dermatomyositis and inclusion body myositis ( Table 2) . We were able to identify incidence rates for 11 disorders. Rates ranged from 0.05/100,000 population per year for Lambert-Eaton myasthenic syndrome to 9/100,000 in spinal muscular atrophy. We found prevalence data for 24 of the 30 disorders. The rates ranged from 0.1/100,000 population for oculopharyngeal muscular dystrophy to 60/100,000 population for post-polio syndrome. Twenty-three disorders had prevalences lower than 50/100,000 and thus are considered to be rare diseases [177] . When we added up the 24 obtained prevalence rates, we found a total of 160/100,000 population.
Age distribution was available for 17 disorders, the majority presenting a uniform age distribution. Friedreich ataxia, Duchenne muscular dystrophy and congenital muscular dystrophies occurred early in life, whereas amyotrophic lateral sclerosis, post-polio syndrome, Lambert-Eaton myasthenic syndrome and inclusion body myositis are revealed later in life. In five disorders, the age distribution was ambiguous.
Gender data for 19 disorders could be retrieved. For the most part, disorders were equally distributed among men and women. Seven disorders showed male predominance, including amyotrophic lateral sclerosis, chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, Lambert-Eaton myasthenic syndrome, Duchenne and Becker muscular dystrophies and facioscapulohumeral dystrophy. Myasthenia gravis, non-dystrophic myotonia, polymyositis and dermatomyositis occurred up to twice as often in women. Table 3 Surveys regarding the prevalence of neuromuscular disorders per 100,000 population * depicted in Fig. 1. 1 Each report includes different combination of disease types, thus outcomes are incomparable. 2 Includes childhood-and adult-onset autosomal dominant proximal spinal muscular atrophy, proximal spinal muscular atrophy type 1, 2, 3, 4 and Kennedy disease. 3 Includes Charcot-Marie-Tooth disease and Xlinked Charcot-Marie-Tooth disease. 4 Includes acute inflammatory demyelinating polyradiculoneuropathy, Guillain-Barré syndrome, acute motor axonal neuropathy, acute motor-sensory axonal neuropathy. 5 Neuropathy associated with paraproteinaemia/monoclonal gammopathy of unknown significance (MGUS). 6 Estimate combined with 'familial motor neurone disease'. 7 Estimate combined with myasthenic syndrome. 8 Includes limb girdle muscular dystrophy, autosomal dominant limb girdle muscular dystrophy type 1B, autosomal recessive limb girdle muscular dystrophy type 2A, 2B, 2C, 2F, 2I. 9 Includes congenital muscular dystrophy, congenital muscular dystrophy type 1A, congenital muscular dystrophy with integrin deficiency and congenital muscular dystrophy, Ullrich type. 10 Includes Steinert myotonic dystrophy and proximal myotonic myopathy. 11 Not included in Fig. 1 our survey rendered only one observation. 12 Includes Thomsen and Becker disease, hyperkalemic and hypokalemic periodic paralysis. 13 Referred to as mitochondrial myopathies. 14 Includes Kearns-Sayre syndrome. 15 Referred to as metabolic myopathies. We found no information on five disorders: progressive spinal muscular atrophy, idiopathic neuralgic amyotrophy, chronic idiopathic axonal polyneuropathy, Pompe's disease and McArdle's disease.
We compared the collected data with two peer reviewed articles dating from 1991 and two reports ( Table 3 , Fig. 1 ) [3] [4] [5] [6] .
DISCUSSION
This study presents epidemiologic data from the recent literature for thirty individual neuromuscular disorders, to serve as a reference for both clinicians, researchers and policymakers. The added value lies in the grouped epidemiology that is made available, enabling comparisons in the order of magnitude as well as the identification of lacunas in the body of knowledge.
When we compared our findings to the earlier peer reviewed survey, data on nine of thirty disorders were available in this survey and only seven were comparable (Table 3 , Fig. 1 ). Amyotrophic lateral sclerosis, Duchenne muscular dystrophy and limb-girdle muscular dystrophy showed stable prevalence estimates over time. Becker muscular dystrophy, facioscapulohumeral dystrophy, myotonic dystrophy and Charcot-Marie-Tooth disease prevalences seemed to have increased considerably. However, in most disorders also the overlap of the ranges of both observations overlapped considerable, except for myotonic dystrophy [3, 4] . The prevalence estimate of myotonic dystrophy, in contrast, appeared to be at least twice as high compared to the 1991 estimate and it displayed less overlapping ranges. The current estimate was based on nine separate observations with prevalence rates ranging from 7.1 to 26.5/100,000 and therefore can hardly be contributed to chance alone. Genetic testing may be one of the contributing factors, as the genetic origin of myotonic dystrophy was identified in 1993, in addition to reaching consensus on diagnostic criteria. The increased prevalence rate in myotonic dystrophy could also be due to improved levels of ascertainment in the included studies compared to the studies reported in the 1991 survey.
We added up the 24 available prevalence estimates" to enable comparison with other diseases. As such, the prevalence of neuromuscular disorders as a group is at least similar to that of Parkinson's disease worldwide (100 -300/100.000) and twice that of multiple sclerosis in Europe (80/100.000). [178, 179] .
As our methods, although systematic, were not designed to capture all studies, the general order of magnitude rather than seemingly exact numbers were presented. For future research it would be interesting to present these data, as well as data on disease subgroups. In our experience however, specific information for subgroups was limited, and data on several subgroups were often combined in changing combinations.
In conclusion, prevalence rates of Becker muscular dystrophy, facioscapulohumeral dystrophy, CharcotMarie-Tooth disease and in particular myotonic dystrophy showed increase, with highly overlapping ranges except for myotonic dystrophy. The summed estimate for neuromuscular disorders as a group represents only the tip of the iceberg. Although neuromuscular disorders are rare as individual disease entities, as a group they are not.
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